PCYC-1121 (#NCT01980628) was a phase 2, multi-center, open-label, non-randomized trial designed to assess the efficacy and safety of single-agent ibrutinib in patients with relapsed/refractory MZL….Among 41 patients with PFS data, those with a mutation in MYD88 (n = 9) had significantly longer median PFS (30.3 months) compared with wild type (12.2 months; hazard ratio [HR]: 0.36) (P = .0500; Figure 4B). PFS was also longer in patients with the MYD88 L265P variant (n = 7) compared with wild type (median PFS not reached vs 13.6 months; HR: 0.20) (P = .0174; Figure 5B).